Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co EBIT Margin

The EBIT Margin (Operating Margin) of Beijing Hotgen Biotech Co (688068.SS) as of Nov 5, 2026 is -64.41 %. In the previous year, EBIT Margin (Operating Margin) was -36.33 % — a change of 77.30% (lower).

EBIT Margin

-64.41 %

YoY

77.30%

Last updated:

EBIT Margin (Operating Margin) of Beijing Hotgen Biotech Co is 2025 -64.41 % . EBIT Margin (Operating Margin) of Beijing Hotgen Biotech Co was 2024 -36.33 % . It decreases by 77.30% lower compared to the previous year.

Beijing Hotgen Biotech Co's operating (EBIT) margin stands at -64.4%, down from 48.1% several years earlier.

The Beijing Hotgen Biotech Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
29.82 CNY
Jan 1, 2019
18.33 CNY
Jan 1, 2020
24.92 CNY
Jan 1, 2021
48.13 CNY
Jan 1, 2022
30.67 CNY
Jan 1, 2023
3.41 CNY
Jan 1, 2024
-36.33 CNY
Jan 1, 2025
-64.41 CNY
The Beijing Hotgen Biotech Co EBIT Margin history
YEAREBIT MarginYoY
-64.41 %+77.30%
-36.33 %-1,164.65%
3.41 %-88.88%
30.67 %-36.28%
48.13 %+93.19%
24.92 %+35.94%
18.33 %-38.55%
29.82 %+22.48%
24.35 %-2.07%
24.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

EBIT Margin (Operating Margin) of Beijing Hotgen Biotech Co is -64.41 % in 2025.

EBIT Margin (Operating Margin) of Beijing Hotgen Biotech Co changed from -36.33 % to -64.41 %, representing a 77.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Beijing Hotgen Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Beijing Hotgen Biotech Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Beijing Hotgen Biotech Co